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ABSTRACT
Background. Current breast cancer care is based on high-
level evidence from randomized, controlled trials. Despite
these data, there continues to be variability of breast cancer
care, including overutilization of some tests and operations.
To reduce overutilization, the American Board of Internal
Medicine Choosing Wisely Campaign recommends that
professional organizations provide patients and providers
with a list of care practices that may not be necessary.
Shared decision making regarding these services is
encouraged.
Methods. The Patient Safety and Quality Committee of
the American Society of Breast Surgeons (ASBrS) solicited
candidate measures for the Choosing Wisely Campaign.
The resulting list of ‘‘appropriateness’’ measures of care
was ranked by a modified Delphi appropriateness
methodology. The highest-ranked measures were submit-
ted to and later approved by the ASBrS Board of Directors.
They are listed below.
Results. (1) Don’t routinely order breast magnetic reso-
nance imaging in new breast cancer patients. (2) Don’t
routinely excise all the lymph nodes beneath the arm in
patients having lumpectomy for breast cancer. (3) Don’t
routinely order specialized tumor gene testing in all new
breast cancer patients. (4) Don’t routinely reoperate on
patients with invasive cancer if the cancer is close to the
edge of the excised lumpectomy tissue. (5) Don’t routinely
perform a double mastectomy in patients who have a single
breast with cancer.
Conclusions. The ASBrS list for the Choosing Wisely
campaign is easily accessible to breast cancer patients
online. These measures provide surgeons and their patients
with a starting point for shared decision making regarding
potentially unnecessary testing and operations.
When surveyed, nearly three of four U.S. physicians say
‘‘doctors’’ order unnecessary tests and procedures. A sim-
ilar proportion report that they themselves order
unnecessary studies and interventions as often as once per
week and that almost half of their patients request unnec-
essary tests on a weekly basis as well.1 These personal
observations from ‘‘doctors’’ are accompanied by objective
evidence of variation in the quality and value of care
delivered to breast cancer patients.2 Both underutilization
of evidence-based care and overutilization of unnecessary
services have been documented.3–18 The former can lead to
worse cancer outcomes, whereas the latter increases the
cost of care without increasing value.16 To address these
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concerns across all specialties, the American Board of
Internal Medicine (ABIM) Foundation launched an initia-
tive to improve ‘‘appropriateness’’ of medical care in the
United States. The Choosing Wisely campaign was
launched in 2012, and more than 70 professional organi-
zations have now contributed lists of appropriateness of
care.1 The goals of this program are to ‘‘promote conver-
sations between clinicians and patients by helping patients
choose care that is supported by evidence and truly nec-
essary.’’ The campaign empowers patients to engage their
care providers in a thoughtful discussion of the benefits,
risks, and effectiveness of the services offered to patients.
The inspiration for Choosing Wisely came from
Howard Brody in 2010, when he challenged specialty
societies to create ‘‘top 5’’ lists of tests and procedures that
had not been shown to provide meaningful benefits to some
patients for which they were ordered.19 Nine societies
submitted lists in 2012. An increasing number have joined
each year since that time. The purpose of the report
described herein is to describe the American Society of
Breast Surgeons (ASBrS) effort to identify, create, and
endorse five measures of appropriate care.
METHODS
The ASBrS has more than 3000 surgeon and associate
members.20 After approval from its Board of Directors,
their Quality Committee (QC) solicited potential ‘‘appro-
priateness measures’’ of breast care from the general and
QC membership in 2014 and 2015. The QC then corre-
sponded with the ABIM to establish the scope and clarity
of the ABIM mission. The QC (13 members) were pro-
vided with the Choosing Wisely goals and existing
‘‘choices’’ previously recommended by other organizations
for breast cancer (Table 1).21 Committee members
received the following instructions to rank our final list of
38 choices:
1. To rank for appropriateness and value of care; value to
be characterized by both quality of care and ‘‘burdens
of care.’’22,23
2. To rank based on the ‘‘importance’’ criteria of the
National Quality Forum for quality measures—impor-
tance, scientific acceptability, feasibility, and
usability.24
Two rounds of modified Delphi process ranking were
performed electronically: March 2014 and July 2015.25,26
A complete Delphi process of ranking continues until all
participants are in uniform agreement; our process of two
rounds was therefore a ‘‘modified’’ Delphi process.
Each potential choice for a measure of appropriateness
was ranked on a scale of 1 (no value or importance) to 9
(highest possible value or importance). After the first
round, a spreadsheet of median scores was provided to
committee members, allowing opportunity for participants
to lobby for either increasing or decreasing a choice’s
‘‘rank.’’
The final voting panel included nine QC members.
Appropriateness of a measure is achieved in a panel of nine
with a median score of 7–9, if there is no major ‘‘dis-
agreement’’ between panelists, as defined by fewer than
three panelists scoring the measure from 1 to 3.25 There
were 16 choices deemed appropriate by this method. The
top 5 choices had median ranks of 8 or 9. Four of these top
5 choices were already included in the Choosing Wisely
Campaign from other organizations, based on ABIM pol-
icy, and these were excluded from our list. Their domains
of appropriateness were to encourage needle biopsy as the
preferred method of diagnosis, limit routine mammography
of reconstructed breasts after mastectomy and discourage
the use of pre- and postoperative systemic imaging in
asymptomatic patients with breast cancer (Table 1). To
finish our list of five, we used the next highest-ranked
choices. The final list of five choices was then formatted in
the style specified by the ABIM. The list was submitted to
the ABIM and a manuscript was drafted and later approved
by the ASBrS Research Committee and Board of Directors
on April 12, 2016.
RESULTS
Five Tests or Interventions Physicians and Patients
Should Question
1. Don’t routinely order breast magnetic resonance
imaging (MRI) in new breast cancer patients.27–34
After a new diagnosis of breast cancer, breast MRI can
be useful in selected patients, to aid treatment
decisions, including but not limited to those with
occult breast cancer presenting with axillary metas-
tases or patients with genetic mutations predisposing to
increased breast cancer risk. However, there is a lack
of evidence that routine use of MRI lessens cancer
recurrence, death from cancer, or the need for reop-
eration after partial breast removal (lumpectomy)
surgery. The routine use of MRI is associated with
an increased need for subsequent breast biopsy proce-
dures, delays in time to treatment, and higher cost of
care. In addition, more patients may undergo mastec-
tomy with routine use of MRI due to MRI detection of
findings of uncertain significance that result in
increased patient anxiety and their subsequent decision
to undergo mastectomy even without proof of other
cancer(s).
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2. Don’t routinely excise all the lymph nodes beneath the
arm in patients having partial breast removal (lumpec-
tomy) for breast cancer when only one or two contain
cancer.28,35,36
After a new diagnosis of invasive breast cancer, most
patients undergoing partial breast removal (lumpec-
tomy) benefit from a ‘‘sentinel node (SN) mapping
surgery’’—a procedure that removes a small number of
lymph nodes beneath the arm that drains the known
cancer. In the past, patients found to have cancer in
any SN underwent extra surgery to remove more
nodes. Recent evidence suggests that further node
surgery is not necessary in patients with cancer found
in fewer than three SN, if the patient receives other
recommended cancer treatments.
3. Don’t routinely order specialized tumor gene testing in
all new breast cancer patients.28,37–41
There are multiple, new, tumor ‘‘multigene signature’’
tests that provide selected breast cancer patients with
information about their risk of distant cancer recur-
rence, dying of cancer, or the likelihood that they will
benefit from chemotherapy. These tests are helpful in
selected patients, including those with early-stage,
hormone-receptor–positive cancers with ‘‘low’’ scores
on 21 gene recurrence testing, who can safely omit
chemotherapy. There is no evidence that these types of
tests should be used routinely. They should not be
performed in patients who indicate that the test results
would not change their choice of treatment.
4. Don’t routinely reoperate on patients if the cancer is
close to the edge of the excised lumpectomy tis-
sue.28,42–45
Patients undergoing partial breast removal (lumpec-
tomy) of the breast and whole breast radiation for
invasive cancer benefit from reoperation to excise
more breast tissue if microscopic review of the
lumpectomy breast tissue indicates that cancer cells
are present at the tissue edge. However, if cancer cells
are close to the edge, but not at the actual edge, then
recent evidence indicates that reoperation is not
mandatory.
5. Don’t routinely perform a double mastectomy in
patients who have a single breast with cancer.46–53
After a new diagnosis of breast cancer in a single
breast, many patients desire removal of both breasts,
believing their cancer risk in the other breast is high
TABLE 1 Breast appropriateness measures in the Choosing Wisely Campaign
Society Recommendation
AMDA The Society for Post-Acute and Long-
Term Care Medicine
Don’t recommend screening for breast, colorectal or prostate cancer if life expectancy is
estimated to be less than 10 years
American Geriatrics Society Don’t recommend screening for breast, colorectal, prostate, or lung cancer without considering
life expectancy and the risks of testing, overdiagnosis, and overtreatment
American Society of Clinical Oncology Don’t use combination chemotherapy (multiple drugs) instead of chemotherapy with one drug
when treating an individual for metastatic breast cancer unless the patient needs a rapid
response to relieve tumor-related symptoms
American Society of Clinical Oncology Don’t perform surveillance testing (biomarkers) or imaging (PET, CT, and radionuclide bone
scans) for asymptomatic individuals who have been treated for breast cancer with curative
intent
American Society of Clinical Oncology Don’t perform PET, CT, and radionuclide bone scans in the staging of early cancer at low risk for
metastasisa
American Society for Radiation Oncology Don’t initiate whole breast radiotherapy as a part of breast conservation therapy in women age
C50 years with early-stage, invasive breast cancer without considering shorter treatment
schedules
American Society for Radiation Oncology Don’t routinely recommend follow-up mammograms more often than annually for women who
have had radiotherapy following breast conserving surgery
American Society for Radiation Oncology Don’t routinely use intensity modulated radiotherapy (IMRT) to deliver whole breast
radiotherapy as part of breast conservaiton therapy
American Society of Plastic Surgeons Avoid performing routine and follow-up mammograms of reconstructed breast after
mastectomiesa
American Society of Plastic Surgeons Avoid using drains in breast reduction mammoplasty
American Society of Plastic Surgeons Avoid performing routine mammograms before breast surgery
American College of Surgeons Don’t perform axillary lymph node dissection for clinical stages I and II breast cancer with
clinically negative lymph nodes without attempting sentinel node biopsya
Commission on Cancer Don’t perform surgery to remove a breast lump for suspicious findings unless needle biopsy
cannot be donea
a Choices that were ranked in the ‘‘highest tier’’ by the ASBrS but not included in the ASBrS list to avoid redundancy
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and their cancer cure rate will be improved with
double mastectomy. Double mastectomy should not be
routinely performed in average-risk patients until they
have been provided with adequate understandable
information about the generally low risk that they will
develop cancer in the other breast and the minimal
effectiveness, if any, of double mastectomy to improve
their life expectancy or survival from breast cancer.
DISCUSSION
The Choosing Wisely campaign was launched to
advance the patient-provider dialogue such that unneces-
sary medical tests, treatments, and procedures would be
used less often.1 To accomplish this, the ABIM recom-
mended that professional organizations provide the ABIM
with ‘‘five things providers and patients should question.’’ 1
Conceptually, the provider stakeholders create lists of
domains of care decisions intended to spur conversations
between providers, patients, and payers about appropriate
care, resulting in less ‘‘waste.’’54,55 This process is in
alignment with widely accepted principles to increase the
‘‘value’’ of healthcare, by lowering cost, promoting patient
engagement, and creating a result that is measurable.56 If
initiatives to increase adherence to Choosing Wisely
choices are successful, then the national cost of healthcare
is likely to decrease. In a cohort of 22,000 patients enrolled
in a single insurance plan in the state of Washington, an
estimated cost savings of $29 million was achieved through
increased adherence to five Choosing Wisely choices.10
After first recognizing and then taking ownership of the
effort to reduce overutilization of services, the ASBrS
developed a list of measures that were intended to improve
appropriateness of testing and surgery in patients with
breast cancer. Measures were chosen that were deemed
important by the criteria of the NQF for quality measure
development.24 These criteria included but were not lim-
ited to scientific support, evidence of variability of care,
and feasibility of use. In the ABIM campaign, all measure
choices should be usable, because they only require the
provider to discuss the measure with the patient. Patient
use and understanding of the Choosing Wisely choices
also is facilitated by the ABIM’s required formatting to
include simple, understandable, and brief declarative
statements, usually beginning the statement with ‘‘Don’t.’’
Other organizations that care for patients with breast
cancer have submitted their Choosing Wisely Lists to the
ABIM (Table 1).21 All used different methods for devel-
oping and prioritizing their lists. None used our modified
Delphi ranking process; yet, independent of these other
organizations, 4 of our 5 top choices were already selected
by them. This concordance between developers using dif-
ferent methodologies supports the importance and potential
impact of these specific measures.
A systematic review of the literature for each of our
Choosing Wisely choices is not the intent of this report.
Background information, comprehensive reviews, and evi-
dence-based support for each of our measures is referenced.
It is important to note that our ‘‘choices’’ are not meant to
infer that the test or procedure endorsed in our list is a
‘‘never should occur’’ event akin to ‘‘wrong site’’ surgery.
For example, we recommend against ‘‘routine MRI’’ in new
breast cancer patients, but MRI imaging can be useful in
selected patients to aid treatment decisions, including but
not limited to those with occult breast cancer presenting
with Paget’s disease of the nipple or with axillary metas-
tases or patients with mutations predisposing to increased
breast cancer risk.27 Rather, the services listed should be
discussed with patients and shared decision making should
occur. There may be circumstances in which best, highest-
quality care is different from the Choosing Wisely state-
ment on a particular topic. Moreover, there are no
benchmarks established for what level of compliance with
our statements would be desirable. Three of our ‘‘choi-
ces’’—on MRI usage, SN surgery, and margin status
decisions—have a high level of evidence supporting them
based on randomized, controlled trials and/or meta-analy-
ses.27–36,42–45 For the other two choices—contralateral
prophylactic mastectomy (CPM) and tumor multigene sig-
nature testing—there is evidence of increasing utilization
that is not always accompanied by evidence of improving
patient-reported and/or clinical outcomes.28,37–41,46–53
CPM rates have increased during the past decade.46–49
In average-risk patients, there is a lack of convincing evi-
dence that CPM improves cancer-specific survival. These
operations often are driven by patient requests for risk
reduction or symmetry. Many patients with unilateral
breast cancer request a CPM, because they perceive that
their cancer risk in the other breast is higher than their
actual risk.51 The inclusion of CPM in the ASBrS choices
for Choosing Wisely does not mean that the ASBrS
endorses a policy of never performing it. We are simply
recommending full education regarding its risks and ben-
efits, emphasizing the importance of a decision-making
process shared by patients and providers. A full discussion
of CPM, its indications and contraindications, is beyond
the scope of this report, but the ASBrS held a consensus
conference in 2016 to further characterize the reasons to
consider or discourage CPM (J. Boughey, Program Direc-
tor for the 2016 Annual Meeting of the American Society
of Breast Surgeons, personal communication, April 12,
2016).
Tumor multigene signature panels that are prognostic
for risk of distant recurrence and overall survival and
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predictive of benefit of chemotherapy are increasingly
utilized after new breast cancers are diagnosed.39–41 In
select patients with invasive cancer, the use of a ‘‘vali-
dated’’ tumor multigene signature testing panel is
appropriate if the patient’s tumor characteristics were
consistent with those used in the panel validation studies
and if the results of testing would affect the patient’s
decisions regarding adjuvant treatment. In this scenario, the
test identifies patients in whom chemotherapy can be
omitted, without harm to distant recurrence risk or overall
survival.39,41 New and emerging tumor multigene panels
hope to do the same, but not all have yet been validated.
Panels also are available for patients with ductal carcinoma
in situ.57 Industry, patients, and patients’ families may
pressure surgeons to order these tests to help direct therapy.
As a result, there is risk of overutilization of testing without
concomitant patient benefit if validated tests are ordered for
patient subgroups not included in the validation studies or
if a patient has already decided to omit a specific adjuvant
therapy due to age, comorbidities, or personal reasons.
The Choosing Wisely campaign is still in its relative
infancy, having been in existence for less than 6 years.
Enthusiasm for its potential impact on improving appro-
priate care and reducing waste is evidenced by the
submission of appropriateness measures by more than 70
professional societies, increasing organizational participa-
tion each year, and the rapid emergence of research
projects and publications measuring adherence to the
Choosing Wisely choices. Many organizations and
regional quality collaboratives are now auditing compli-
ance with the Choosing Wisely choices, using them as a
surrogate measure of quality.58 Most Choosing Wisely
choices also could be crafted into metrics of value or
efficiency. Although results are preliminary, some organi-
zations have already implemented action plans to address
compliance variability.59
We hope that our society’s endorsement of five new
choices for the Choosing Wisely campaign will contribute
to increased delivery of appropriate care and decreased
overall cost of care for breast cancer patients. Plans to
develop five additional measures of appropriateness in the
management of benign breast disease are anticipated.
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